Evidence map›Paper›PMID 25213996›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2014

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05452772 (5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder), which is not on this map. Cited by 382 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
382citing papers in PubMed, 11 pooled it
38.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05452772 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2027Enrolled66ConditionsTobacco Use DisorderArmsPsilocybin, Niacin
3 · Its place in the literature

Who cites it

382 citing papers in PubMed, 11 syntheses or guidelines pooled it, 888 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Single-crystal structure determination of psilocybin after dehydration.Acta crystallographica. Section C, Structural chemistry · 2026
    Article
  19. Review
  20. Article

322 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew W JohnsonDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA mwj@jhu.edu.
Albert Garcia-RomeuDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mary P CosimanoDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Roland R GriffithsDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Human Clinical Pharmacology of Emerging Drugs of Abuse (Club Drugs)R01DA003889 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GRIFFITHS, ROLAND R · 1985 to 2017
$7.6M
NIDA NIH HHS R01 DA003889NIDA NIH HHS T32 DA007209NIDA NIH HHS T32DA07209
6 · The paper itself

Abstract

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.

Indexed as

AttitudeBehavior, AddictiveBiomarkersCarbon MonoxideCognitive Behavioral TherapyCombined Modality TherapyCotinineDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedNicotinic AgonistsPilot ProjectsPsilocybinSerotonin Receptor AgonistsBiomarkersCarbon MonoxideCotinineNicotinic AgonistsPsilocybinSerotonin Receptor AgonistsaddictionHallucinogennicotinepsilocybinpsychedelicsmoking cessationtobacco

Identifiers

PMID25213996
PMCPMC4286320
OpenAlexW2122459973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.